Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Steg

Showing results (861-870 of 962) with videos related to

Pageof 97
Sort By:
Thrombosis and Haemostasis|August 1, 2019
Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS RegistryBirgit Vogel, Jaya Chandrasekhar, Usman Baber, et al.
American Heart Journal|November 23, 2022
Rationale and design for the myocardial ischemia and transfusion (MINT) randomized clinical trialJeffrey L Carson, Maria Mori Brooks, Bernard R Chaitman, et al.
JAMA|September 1, 2014
Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trialMichelle L O'Donoghue, Eugene Braunwald, Harvey D White, et al.
Archives of Cardiovascular Diseases|February 9, 2025
Machine learning to detect recent recreational drug use in intensive cardiac care unitsNathan El Bèze, Kenza Hamzi, Patrick Henry, et al.
NEJM Evidence|December 23, 2024
Restrictive versus Liberal Transfusion in Myocardial Infarction - A Patient-Level Meta-AnalysisJeffrey L Carson, Dean A Fergusson, Helaine Noveck, et al.
Heart (British Cardiac Society)|August 15, 2023
Prevalence and impact of recreational drug use in patients with acute cardiovascular eventsThéo Pezel, Jean-Guillaume Dillinger, Antonin Trimaille, et al.
Journal of the American College of Cardiology|January 18, 2020
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary SyndromeVera A Bittner, Michael Szarek, Philip E Aylward, et al.
The Lancet. Public Health|September 20, 2020
Hospital admissions for acute myocardial infarction before and after lockdown according to regional prevalence of COVID-19 and patient profile in France: a registry studyJules Mesnier, Yves Cottin, Pierre Coste, et al.
Circulation|November 2, 2022
The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI TrialRoxana Mehran, Philippe Gabriel Steg, Marc A Pfeffer, et al.
Journal of the American College of Cardiology|November 15, 2018
Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES TrialMichael Szarek, Harvey D White, Gregory G Schwartz, et al.
Pageof 97

Showing results (861-870 of 962) with videos related to

Sort By:
Pageof 97
Thrombosis and Haemostasis|August 1, 2019
Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS RegistryBirgit Vogel, Jaya Chandrasekhar, Usman Baber, et al.
American Heart Journal|November 23, 2022
Rationale and design for the myocardial ischemia and transfusion (MINT) randomized clinical trialJeffrey L Carson, Maria Mori Brooks, Bernard R Chaitman, et al.
JAMA|September 1, 2014
Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trialMichelle L O'Donoghue, Eugene Braunwald, Harvey D White, et al.
Archives of Cardiovascular Diseases|February 9, 2025
Machine learning to detect recent recreational drug use in intensive cardiac care unitsNathan El Bèze, Kenza Hamzi, Patrick Henry, et al.
NEJM Evidence|December 23, 2024
Restrictive versus Liberal Transfusion in Myocardial Infarction - A Patient-Level Meta-AnalysisJeffrey L Carson, Dean A Fergusson, Helaine Noveck, et al.
Heart (British Cardiac Society)|August 15, 2023
Prevalence and impact of recreational drug use in patients with acute cardiovascular eventsThéo Pezel, Jean-Guillaume Dillinger, Antonin Trimaille, et al.
Journal of the American College of Cardiology|January 18, 2020
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary SyndromeVera A Bittner, Michael Szarek, Philip E Aylward, et al.
The Lancet. Public Health|September 20, 2020
Hospital admissions for acute myocardial infarction before and after lockdown according to regional prevalence of COVID-19 and patient profile in France: a registry studyJules Mesnier, Yves Cottin, Pierre Coste, et al.
Circulation|November 2, 2022
The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI TrialRoxana Mehran, Philippe Gabriel Steg, Marc A Pfeffer, et al.
Journal of the American College of Cardiology|November 15, 2018
Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES TrialMichael Szarek, Harvey D White, Gregory G Schwartz, et al.
Pageof 97